Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

How RSA Insurance Group plc (RSA) Measures Up As a GARP Investment

LONDON — A popular way to dig out reasonably priced stocks with robust growth potential is through the Growth At A Reasonable Price, or GARP, strategy.

This theory uses the price-to-earnings to growth (PEG) ratio to show how a share’s price weighs up in relation to its near-term growth prospects — a reading below 1 is generally considered decent value for money.

Today I am looking at RSA Insurance Group plc (LON:RSA) to see how it measures up.

What are RSA’s earnings expected to do?

2013 2014
EPS Growth 27% 5%
P/E Ratio 9.6 9.2
PEG Ratio 0.4 1.9

Source: Digital Look.

RSA Insurance Group plc (LON:RSA) is expected to recover from last year’s 20% earnings per share (EPS) decline in the coming years, although growth in 2014 is expected to decelerate sharply from that of the current year.

The explosive EPS increase forecast for 2013 drives the corresponding PEG ratio into bargain territory, although slower growth next year pushes it back above the benchmark of 1. Still, a price-to-earnings (P/E) ratio below 10 for both of these years underlines its current position as a value stock — any reading under 10 is considered excellent value.

Does RSA provide decent value against its rivals?

FTSE 100 Non-life Insurance
Prospective P/E Ratio 14.9 10.5
Prospective PEG Ratio 4.5 1.8

Source: Digital Look.

RSA trounces the FTSE 100 in terms of both forward PEG and P/E ratings. The firm also beats its non-life insurance rivals when considering these measures, although both metrics are much closer versus its sector counterparts.

In my opinion, RSA Insurance Group plc (LON:RSA) qualifies as a classic GARP stock owing to its ultra-attractive PEG rating, with a pleasing P/E rating amplifying its value investment case.

Foreign markets primed to drive earnings skywards
RSA Insurance Group plc (LON:RSA) announced in May’s interims that net written premiums rose 5% during its first quarter to £2.3 billion. The company also reported a slight uptick in premiums within its key markets of the U.K. and Western Europe, to £952 million, although activity in Scandinavia remained static at £694 million.

However, exceptional growth in other markets looks set to drive earnings expansion in the coming years. Indeed, net written premiums in developing markets increased 16% in January, February and March, to £325 million, while in Canada the number rose 18% to £359 million.

And the company is complementing strong organic growth with bubbly M&A activity in these markets — in fact, acquisitions in Canada and Argentina in recent years have helped to push growth in these regions.

Appetite for RSA Insurance Group plc (LON:RSA)’s shares moderated recently after management announced plans to rebase the dividend in order to drive future growth. The firm is still on course to deliver chunky shareholder payouts, however — a yield of 5.9% is forecast for this year and next.

So for those seeking appetising growth prospects as well as decent dividend income, I believe that RSA Insurance Group plc (LON:RSA) is a stock worthy of serious consideration.

The article How RSA Insurance Measures Up As a GARP Investment originally appeared on and is written by Royston Wild.

Royston does not own shares in RSA Insurance Group. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!